Revenue: As of FY2026, the actual value is USD 83.17 B, missing the estimate of USD 83.3 B.EPS: As of FY2026, the actual value is USD 0.4, missing the estimate of USD 1.5833.EBIT: As of FY2026, the actual value is USD 772 M.<h4>Segment Overview</h4>Albertsons Companies, Inc. operates as one reportable segment, meaning all financial and operational metrics are reported at the company level .<h4>Segment Revenue</h4><ul><li>Net Sales and Other Revenue: Increased by 3.5% to $83,172.5 million in fiscal 2025 from $80,390.9 million in fiscal 2024, primarily due to a 2.0% increase in identical sales, driven by pharmacy sales, and the impact of the 53rd week, partially offset by store closures and lower fuel sales .</li><li>Identical Sales (excluding fuel): Increased by 2.0% in fiscal 2025, matching the 2.0% increase in fiscal 2024, following a 3.0% increase in fiscal 2023 .</li><li>Digital Sales: Increased by 21% in fiscal 2025 compared to fiscal 2024 .</li><li>Net Sales and Other Revenue by Product Type (Fiscal 2025 vs. Fiscal 2024):<ul><li>Non-perishables: $40,624.8 million (48.8% of total) in fiscal 2025 vs. $40,102.8 million (49.9% of total) in fiscal 2024 .</li><li>Fresh: $26,024.2 million (31.3% of total) in fiscal 2025 vs. $25,507.3 million (31.7% of total) in fiscal 2024 .</li><li>Pharmacy: $11,414.9 million (13.7% of total) in fiscal 2025 vs. $9,597.2 million (11.9% of total) in fiscal 2024 .</li><li>Fuel: $3,803.0 million (4.6% of total) in fiscal 2025 vs. $3,980.6 million (5.0% of total) in fiscal 2024 .</li><li>Other: $1,305.6 million (1.6% of total) in fiscal 2025 vs. $1,203.0 million (1.5% of total) in fiscal 2024 .</li></ul></li></ul><h4>Operational Metrics</h4><ul><li>Net Income: $217.4 million in fiscal 2025, compared to $958.6 million in fiscal 2024 and $1,296.0 million in fiscal 2023, with fiscal 2025 including a -$599.8 million charge, net of tax, related to the Opioid Settlement Framework .</li><li>Adjusted Net Income: $1,209.3 million in fiscal 2025, compared to $1,382.4 million in fiscal 2024 and $1,693.7 million in fiscal 2023 .</li><li>Adjusted EBITDA: $3,901.5 million (4.7% of Net sales and other revenue) in fiscal 2025, compared to $4,004.7 million (5.0% of Net sales and other revenue) in fiscal 2024 and $4,317.7 million in fiscal 2023 . The decrease in fiscal 2025 was partially offset by an estimated incremental $68 million from the extra week .</li><li>Gross Margin Rate: Decreased to 27.2% in fiscal 2025 from 27.7% in fiscal 2024 . Excluding fuel and LIFO impacts, the rate decreased by 59 basis points, mainly due to strong growth in lower-margin pharmacy sales and increased digital sales delivery and handling costs .</li><li>Selling and Administrative Expenses: Increased to 26.3% of Net sales and other revenue in fiscal 2025, up from 25.6% in fiscal 2024 . Excluding fuel and Opioid Settlement Framework impacts, these expenses as a percentage of Net sales and other revenue decreased by 38 basis points, mainly due to sales leveraging of employee costs and lower Merger-related costs, partially offset by increased business transformation costs .</li><li>(Gain) Loss on Property Dispositions and Impairment Losses, Net: A net gain of $12.2 million in fiscal 2025, primarily from real estate sales, partially offset by retail store and technology asset impairment losses . This compares to a net loss of -$95.8 million in fiscal 2024, mainly from asset impairments including micro-fulfillment centers .</li><li>Interest Expense, Net: $504.2 million in fiscal 2025, up from $459.8 million in fiscal 2024, primarily due to higher average outstanding borrowings .</li><li>Income Tax Expense: $50.4 million in fiscal 2025 (18.8% effective tax rate) compared to $171.1 million in fiscal 2024 (15.1% effective tax rate) . The increase in rate for fiscal 2025 was mainly due to discrete state income tax benefits recognized in fiscal 2024 .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by Operating Activities: $2,366.7 million in fiscal 2025, a decrease from $2,680.6 million in fiscal 2024 . This decrease was driven by lower Adjusted EBITDA, higher cash paid for taxes, insurance claims, operating leases, and business transformation costs, and changes in working capital, partially offset by lower Merger-related costs and pension contributions .</li><li>Net Cash Used in Investing Activities: -$1,679.4 million in fiscal 2025, primarily for $1,833.6 million in property, equipment, and intangibles, partially offset by $109.5 million from asset sales .</li><li>Net Cash Used in Financing Activities: -$782.2 million in fiscal 2025, mainly due to common stock repurchases, dividends, and debt financing costs, partially offset by proceeds from debt issuances .</li></ul><h4>Unique Metrics</h4><ul><li>Loyalty Members: Grew 12% to 51.2 million members in fiscal 2025 compared to fiscal 2024 .</li><li>Stores: Albertsons Companies, Inc. operated 2,244 stores as of February 28, 2026, having opened 9 new stores and closed 35 during fiscal 2025 .</li><li>Remodels: Completed 94 remodels in fiscal 2025 .</li><li>Own Brands Retail Sales: Totaled $16.9 billion in fiscal 2025 .</li><li>Own Brands Manufacturing: 9.9% of Own Brands products were manufactured in Company-owned facilities in fiscal 2025 .</li><li>Capital Expenditures: Approximately $1,833.6 million in fiscal 2025 .</li></ul><h4>Outlook / Guidance</h4>For fiscal 2026, Albertsons Companies, Inc. anticipates capital expenditures to range from $2.0 billion to $2.2 billion . The Board increased the quarterly cash dividend by 13% to $0.17 per common share, payable on May 8, 2026 . Additionally, the Board authorized a $900 million increase to the share repurchase program, bringing the total remaining authorization to $2.0 billion as of April 14, 2026 .

Albertsons | 10-K: FY2026 Revenue Misses Estimate at USD 83.17 B